Defactinib and VS‐471810 (surrogate for defactinib in nonclinical mouse studies) are FAK inhibitors that have shown synergistic antitumor activity in combination with avutometinib in human cancer models by blocking this known mechanism of adaptive resistance to RAS/MAPK pathway inhibition via FAK activation.11, 12. Here, PTK2 is linked to cancer.